AstraZeneca stock gains despite pipeline setbacks and YTD underperformance

AstraZeneca stock is edging higher as investors weigh pipeline setbacks against solid fundamentals and a year-to-date share price decline versus the wider biotech industry.

AstraZeneca stock (ISIN US6549022043) is trading at 164.02 dollars on the New York Stock Exchange, up 1.48% as of September 3, 2026, according to market data compiled by MarketBeat. The move comes even as the shares remain weaker over the year-to-date period than the broader medical genetics segment.

Share price and relative performance

According to MarketBeat's AstraZeneca overview, the stock stands at 164.02 dollars as of 11:28 AM Eastern on September 3, 2026, representing a 2.39 dollar gain on the session, or 1.48%. The same data set points to a neutral valuation stance with a price to fair value ratio of 0.91 reported by Morningstar in early September 2026, suggesting the shares trade modestly below an internally assessed fair price.

In a recent analyst commentary highlighted by Zacks' analyst blog dated September 3, 2026, AstraZeneca's shares are down 10.7% year to date, while the Zacks Medical - Biomedical and Genetics industry index has gained 10.6% over the same period. The gap of 21.3 percentage points underlines the company's relative underperformance despite the current intraday gain.

Pipeline issues and sector context

A separate Zacks stock commentary published on September 4, 2026 notes that AstraZeneca stock has declined 20% over the past six months and 11.7% so far in 2026, citing pipeline setbacks as a central headwind for investor sentiment. The analysis argues that recent trial disappointments and regulatory delays have weighed on the valuation, even though the overall biopharmaceutical industry benchmark rose 13.0% in the same timeframe, creating a marked performance gap between AstraZeneca and its peers.

For investors, that divergence reinforces the importance of assessing whether upcoming regulatory decisions and data readouts can repair confidence. In breast cancer, for example, CURE reports that the United States Food and Drug Administration extended its review of a key therapy in May to consider additional data, and AstraZeneca has stated that regulators have not yet set a new decision date. The absence of a firm timeline for that approval process adds uncertainty around the near term growth trajectory in oncology, a core profit driver for the group.

Products and oncology focus

AstraZeneca's business remains heavily exposed to oncology, where key products include breast cancer and lung cancer therapies developed in partnership with other major pharmaceutical companies. Recent commentary in CURE describes four breast cancer treatments awaiting regulatory decisions, naming AstraZeneca among the companies depending on new approvals to support revenue growth. As of mid 2026, regulators extended at least one review to evaluate additional data, delaying the potential launch and reinforcing how concentrated the company's growth expectations are in a few high profile oncology indications.

Stock level and investor view

As of September 3, 2026 the latest available New York Stock Exchange quote places AstraZeneca stock at 164.02 dollars, with a one day increase of 1.48% but a year-to-date decline of 10.7% versus a 10.6% gain for the biomedical and genetics industry index. That combination of modest discount to fair value, near term price recovery and longer term underperformance invites a more detailed look at trial milestones and regulatory decision dates as the next potential catalysts.

AstraZeneca stock fact box

• Company: AstraZeneca PLC
• ISIN: US6549022043
• Ticker: AZN
• Trading venue: NYSE
• Price (as of September 3, 2026, 11:28): 164.02 USD
• Market capitalization: data in USD as of latest quote
• Sector / Industry: Pharmaceuticals / Biotechnology
• Index membership: FTSE 100